Drugs / amibegron
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 314 trials | ||||||
| Phase 3 | NCT00535340 | Mar → Aug 2007 | anxiety disorder | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00432614 | Jan 2007 → Feb 2008 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00397098 | Nov 2006 → Sep 2007 | anxiety disorder | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00385307 | Sep 2006 → Nov 2007 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00345098 | May 2006 → Feb 2008 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00319709 | Apr 2006 → Apr 2007 | depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00332891 | Mar 2006 → Apr 2007 | anxiety disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00266747 | Dec 2005 → Jan 2007 | anxiety disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00252356 | Sep 2005 → Jan 2007 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00855530 | Sep 2005 → Jul 2007 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00252330 | Sep 2005 → Jan 2007 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00252343 | Sep 2005 → Feb 2007 | anxiety disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00825058 | Nov 2003 → May 2004 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00825019 | Sep 2003 → Oct 2004 | major depressive disorder | Sanofi | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amibegron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00855530 ↗ |
| Known as | Amibegron hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1193948 ↗ |
| Known as | AMIBEGRON HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1193948 ↗ |
| Known as | SR-58611 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1193948 ↗ |
| Known as | SR58611A | “To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).” NCT00855530 ↗13“Drug: amibegron (SR58611A)” NCT00825058 ↗ “amibegron (SR58611A)” NCT00825019 ↗ “amibegron (SR58611A)” NCT00385307 ↗ |
| Action | Activate | “Beta-3 adrenergic receptor agonist” CHEMBL1193948 ↗ |
| Modality | Small molecule | — CHEMBL1193948 ↗ |
| Route | Oral | “oral administration” NCT00432614 ↗ |
| Target | ADRB3 | “Beta-3 adrenergic receptor agonist” CHEMBL1193948 ↗ |